KEYTRUDA (pembrolizumab) 395 mg solution for injection Prescribing Information [External link] | KEYTRUDA (pembrolizumab) 790 mg solution for injection Prescribing Information [External link] | KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Prescribing Information [External link]

KEYTRUDA SC Dosing and Administration Video

Watch the KEYTRUDA SC dosing and administration video for considerations for storage, preparation and administration for your eligible adult patients.

Support and Resources​

KEYTRUDA SC Clinical Data
Interactive Deck​​

Download deck

KEYTRUDA SC Protocol
Fact Sheet​

Download fact sheet

Dosing, Storage and
Administration Guide

Download guide

To order a printed version, please contact us at msdukoncology@msd.com

Dosing and Administration Poster

Download poster

To order a printed version, please contact us at msdukoncology@msd.com

KEYTRUDA SC is licensed for use in adult patients across most KEYTRUDA IV indications, whether alone or in combination with other therapies.^1,2 One such indication is: KEYTRUDA IV and KEYTRUDA SC, in combination with pemetrexed and platinum chemotherapy, are each indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR- or ALK-positive mutations.^1,2
Please consult the SmPC for the full list of indications and further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

KEYTRUDA SC is for adult use only. The safety and efficacy of KEYTRUDA SC in children below 18 years of age have not been established.¹
The approved indications for KEYTRUDA SC have been established based on the MK-3475A-D77 study, which demonstrated non-inferior pharmacokinetics, and comparable efficacy and safety profiles between KEYTRUDA SC and KEYTRUDA.¹
Please refer to individual product SmPCs for full information about dosing, preparation and administration.

References

1. KEYTRUDA (pembrolizumab) Solution for Injection Summary of Product Characteristics (395 mg and 790mg).
2. KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Summary of Product Characteristics.

Supporting documentation

KEYTRUDA (pembrolizumab) 395 mg solution for injection Prescribing Information [External link]
KEYTRUDA (pembrolizumab) 790 mg solution for injection Prescribing Information [External link]
KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.